Event Date: Jul 23, 2014
This presentation will review the efficacy and safety established during the development program for extended release hydrocodone bitartrate (Zohydro ER) and the steps that Zogenix is taking to responsibly market the medication. Further information will be provided to directly address the misinformation that has been widely publicized in the media with regard to its relative potency and relative risk of hydrocodone in terms of risks of abuse, misuse, and diversion. Lastly we will address the issues that have been raised in relation to the FDA Advisory Committee meeting and approval of Zohydro ER.
